The effect of wet cupping therapy on the levels of blood lipids and grade of fatty liver in non-alcoholic patients.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180711040437N1

Enrollment

Registered

2018-08-13

Start date

2018-08-23

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic Fatty Liver Disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Two times wet cupping therapy every two weeks and dietary recommendations of the Association of Obesity. Intervention 2: Control group: Only dietary recommendations

Eligibility

Sex/Gender

All

Age

5 Years to 60 Years

Inclusion criteria

Inclusion criteria: They do not have hyperlipidemia They do not drink alcohol They do not have a history of kidney failure and coronary artery diseases In the last two months, they do not have wet cupping therapy and blood donation They do not have a history of severe movement restrictions

Exclusion criteria

Exclusion criteria: Any treatment or intervention that is carried out during the study and affect the variables of the research. Changes in the patient's condition so that it is not allowed to continue cupping therapy, such as pregnancy. Patients' lack of satisfaction to continue their collaboration in the research project.

Design outcomes

Primary

Measure	Time frame
Cholesterol. Timepoint: Before Intervention, One Month Later of second Wet Cupping Therapy. Method of measurement: Pars Azmoon kit and BT 3000 Device.;Triglyceride. Timepoint: Before Intervention, One Month Later of second Wet Cupping Therapy. Method of measurement: Pars Azmoon kit and BT 3000 Device.;Aspartate Aminotransferase Test. Timepoint: Before Intervention, One Month Later of second Wet Cupping Therapy. Method of measurement: Pars Azmoon kit and BT 3000 Device.	—

Measure

Time frame

Cholesterol. Timepoint: Before Intervention, One Month Later of second Wet Cupping Therapy. Method of measurement: Pars Azmoon kit and BT 3000 Device.;Triglyceride. Timepoint: Before Intervention, One Month Later of second Wet Cupping Therapy. Method of measurement: Pars Azmoon kit and BT 3000 Device.;Aspartate Aminotransferase Test. Timepoint: Before Intervention, One Month Later of second Wet Cupping Therapy. Method of measurement: Pars Azmoon kit and BT 3000 Device.

—

Secondary

Measure	Time frame
Cholesterol Test. Timepoint: Before Intervention and One month later of Second Wet Cupping Therapy. Method of measurement: Pars Azmoon Kit and BT 3000 Device.;Triglyceride. Timepoint: Before Intervention and One month later of Second Wet Cupping Therapy. Method of measurement: Pars Azmoon Kit and BT 3000 Device.;Aspartat Aminotransferase Test. Timepoint: Before Intervention and One month later of Second Wet Cupping Therapy. Method of measurement: Pars Azmoon Kit and BT 3000 Device.	—

Measure

Time frame

Cholesterol Test. Timepoint: Before Intervention and One month later of Second Wet Cupping Therapy. Method of measurement: Pars Azmoon Kit and BT 3000 Device.;Triglyceride. Timepoint: Before Intervention and One month later of Second Wet Cupping Therapy. Method of measurement: Pars Azmoon Kit and BT 3000 Device.;Aspartat Aminotransferase Test. Timepoint: Before Intervention and One month later of Second Wet Cupping Therapy. Method of measurement: Pars Azmoon Kit and BT 3000 Device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Hasan Ghorbani

Gonabad University of Medical Sciences

ghorbani.h@gmu.ac.ir+98 51 5722 3028

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026